Italfarmaco And Jcr Pharmaceuticals Announce Commercialisation Agreement For Givinostat In Japan And Strategic Collaboration In Rare Disease
23/12/2025 23:32
Dec 24 (Reuters) - JCR Pharmaceuticals Co Ltd 4552.T: JCR PHARMACEUTICALS CO LTD: ITALFARMACO AND JCR PHARMACEUTICALS ANNOUNCE COMMERCIALISATION AGREEMENT FOR GIVINOSTAT IN JAPAN AND STRATEGIC COLLABORATION IN RARE DISEASE Source text: ID:nTSxw802ad Further company coverage: 4552.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on JCR Pharmaceuticals
See all newsBrief: JCR Pharmaceuticals Receives Marketing Authorization In Kuwait For Izcargo
Italfarmaco And Jcr Pharmaceuticals Enter Into Exclusive License Agreement For Jr-141 In United States, Europe, And Latin America
Brief: Jcr Pharmaceuticals Receives Orphan Drug Designation For Givinostat In Japan
Brief: Medipal & JCR Dose First Patient In Global Phase I/II Trial OF JR-446 For Mucopolysaccharidosis Type IIIB
Table: Jcr Pharmaceuticals -Q1 group results